Wingtra manufactures professional VTOL (vertical take-off and landing) drones for surveying, mining and agricultural applications. Thanks to its VTOL technology, the startup has grown to become an international company with distribution partners in six continents and over 1000 customer flights.
The startup has now expanded its team with the appointment of Cyril Halter as the new COO. Halter as the new COO. Cyril Halter will be taking over Wingtra’s operations with a focus on the industrialisation and the ramp up of production to enable forecasted triple digit growth over the next years.
Additive manufacturing industry veteran for UrbanAlps
UrbanAlps, the startup famous for its patented Stealth Key, the world’s first 3D metal printed key with unparalleled levels of key duplication, also announced a new appointment.
The startup has appointed Henner Schöneborn, the additive manufacturing industry veteran to its advisory board. He is the co-founder of SLM Solutions, Germany, CTO and Member of the Management Board. Schöneborn was the key driver of SLM´s Additive Manufacturing and Powder Bed Technology innovations. As a CEO of SLM´s Software JV, Schöneborn was responsible for the Additive Intelligence Suite.
UrbanAlps will benefit from Schöneborns expertise to design its Advanced Additive Production Center and to support the management Team for driving the Stealth Key towards large-scale industrialization.
Two commercialisation specialits for Aleva
Aleva Neurotherapeutics, a leading developer of implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson ’s disease and Essential Tremor, has too, announced the appointment of two commercialization specialists, Jeffery B. Jump and Peter Bergsma, to its senior management team
Jump is joining the Aleva Board as Chairman. He brings 40 years of experience in the healthcare industry. His specific areas of expertise are product commercialisation, licensing, and Mergers & Acquisitions in the healthcare sector.
Bergsma has joined Aleva as Director of Commercialization. He will lead the company’s ‘Go to Market’ strategy and will initially focus on obtaining commitment from key implantation centers in the DACH-region. These centers are expected to conduct their first Aleva implantations during early 2019, with subsequent commercial roll-out across other EU countries.
Photo l-r: Cyril Halter, Henner Schöneborn and Jeffery B. Jump